Scisparc Ltd. (SPRC) SEC Filings — 2024
43 SEC filings for Scisparc Ltd. (SPRC) in 2024.
Filings
- SciSparc Trial for Autism Gets Green Light — 6-K · Dec 31, 2024
- SciSparc Ltd. Updates on AutoMax Motors' $13M Vehicle Delivery — 6-K · Dec 26, 2024
- SciSparc Updates Spin-off of Pharma Portfolio — 6-K · Dec 17, 2024
- SciSparc Ltd. Files November 2024 6-K Report — 6-K · Nov 29, 2024
- SciSparc Ltd. Amends Merger Agreement — 6-K · Nov 27, 2024
- SciSparc Ltd. Files 6-K Report — 6-K · Nov 4, 2024
- SciSparc Ltd. Shareholders Approve All Proposals at AGM — 6-K · Oct 23, 2024
- SciSparc Annual Meeting Adjourned Due to Lack of Quorum — 6-K · Oct 22, 2024
- SciSparc Ltd. Postpones Annual General Meeting — 6-K · Sep 27, 2024
- SciSparc to Sell Stake in MitoCareX — 6-K · Sep 26, 2024
- SciSparc Gets FDA Nod for Tourette Syndrome Phase IIb Trial — 6-K · Sep 23, 2024
- SciSparc & Clearmind Patent for Ibogaine Therapy — 6-K · Sep 16, 2024
- SciSparc Ltd. Amends Bridge Loan Agreement — 6-K · Sep 11, 2024
- SciSparc & Clearmind Patent Application for MDMA Treatment — 6-K · Sep 6, 2024
- SciSparc & Clearmind Announce Ketamine Therapy Publication — 6-K · Aug 29, 2024
- SciSparc submits IND for Tourette Syndrome trial — 6-K · Aug 26, 2024
- SciSparc Ltd. Announces Annual Shareholder Meeting for Oct 1 — 6-K · Aug 22, 2024
- SciSparc Enrolls First 5 Patients in SCI-210 Trial — 6-K · Aug 20, 2024
- SciSparc Ltd. Licenses SCI-160 Program, Terminates Co-Development Deal — 6-K · Aug 19, 2024
- SciSparc Ltd. Amends Merger Agreement — 6-K · Aug 14, 2024
- SciSparc Ltd. Files 6-K Amid Merger Agreement — 6-K · Aug 13, 2024
- SciSparc's MEAI Shows Weight Loss Potential in New Study — 6-K · Aug 6, 2024
- SciSparc's MitoCareX Shows Promise in Lung Cancer Treatment — 6-K · Jul 23, 2024
- SciSparc Signs $6M Pain Treatment Out-Licensing LOI — 6-K · Jul 17, 2024
- SciSparc Files US Patent for Weight Loss & Metabolic Syndrome Drug — 6-K · Jul 16, 2024
- SciSparc to Spin Off Clinical Pharma Portfolio — 6-K · Jul 8, 2024
- SciSparc Ltd. Amends Bridge Loan Agreement — 6-K · Jun 14, 2024
- SciSparc Secures European Patent for Tourette Syndrome Treatment — 6-K · Jun 3, 2024
- SciSparc Ltd. Files Amendment to Annual Report on Form 20-F — 20-F/A · May 2, 2024
- SciSparc Ltd. to Merge with AutoMax Motors Ltd. — 6-K · Apr 11, 2024
- SciSparc Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Apr 1, 2024
- SciSparc & Clearmind Patent for Depression Treatment — 6-K · Mar 27, 2024
- SciSparc Doses First Patient in Autism Trial — 6-K · Mar 15, 2024
- SciSparc's MitoCareX venture shows promise in glioblastoma study — 6-K · Mar 13, 2024
- SciSparc Secures Canadian Patent for Opioid Reduction Tech — 6-K · Mar 8, 2024
- Scisparc Ltd. SC 13G Filing — SC 13G · Mar 6, 2024
- SciSparc Delivers ASD Treatment, Dosing to Begin in Clinical Trial — 6-K · Feb 29, 2024
- SciSparc & Clearmind File 3 New Patents for MDMA, Ibogaine, Ketamine — 6-K · Feb 27, 2024
- SciSparc & Clearmind Bolster Psychedelic Patent Portfolio — 6-K · Feb 20, 2024
- SciSparc Loses Key License Agreement with Dekel Pharma — 6-K · Feb 12, 2024
- SciSparc Begins Patient Recruitment for Autism Clinical Trial — 6-K · Jan 29, 2024
- SciSparc Secures $20M Equity Line with YA II PN, Ltd. — 6-K · Jan 25, 2024
- SciSparc Provides $1.4M Bridge Loan for Israeli Vehicle Importer Acquisition — 6-K · Jan 22, 2024